Valuing a French pharmacy: inventory, margin and adjusted EBITDA before acquisition

Valuing a French pharmacy requires more than applying a multiple. Revenue, gross margin, adjusted EBITDA, inventory, location, team, pharmacist-owner role, financing and regulatory constraints must be read together. A multiple is meaningless if accounting adjustments, stock and debt capacity are inconsistent.

A French pharmacy is a regulated business, a healthcare activity and a patrimonial asset. A buyer must analyse price like a lender, a pharmacist and a CEO: normalised profitability, cash needs, team quality, seasonality and dependence on the outgoing owner all matter. Strong regulatory specifics add to this: operation requires a qualified pharmacist-owner registered with the Order, the goodwill is inseparable from the pharmacy licence, and the margin on reimbursed medicines is capped by the regulated smoothed degressive margin (MDL) and supplemented by dispensing fees. These constraints weigh on value as much as the figures: a pharmacy is first a public-health tool before being a tradeable asset, and its profitability hinges on the mix between regulated reimbursed medicine and free-margin para-pharmacy.

The pharmacy market is sensitive to location, volumes, margins, competition, services and investment needs. For a buyer, the real question is not just what the pharmacy is worth, but how much debt it can support after owner remuneration and inventory financing.

The useful starting point for valuing a french pharmacy: inventory, margin and adjusted ebitda before acquisition is practical: should valuation start with revenue?. A quick answer helps, but it is not enough unless the file connects financial statements, p&l, ledgers and tax returns for three years. with the main operating risk: valuing the pharmacy on revenue without reviewing margin.. For valuing a french pharmacy: inventory, margin and adjusted ebitda before acquisition, the link between decision, evidence and timing is what turns the article into a working tool for founders and finance teams.

• Pharmacists preparing a first acquisition.
• Owners who want to sell with clean, readable accounts.
• Banks and investors analysing debt capacity.
• Accountants and advisers preparing sector due diligence.
• Buyers distinguishing asking price, economic value and available cash.

In a real French file on valuing a french pharmacy: inventory, margin and adjusted ebitda before acquisition, the goal is not to tick an administrative checklist: the company must show why the decision is consistent with the available facts. For "Should valuation start with revenue?", the practical reading is: Revenue is a benchmark, not a valuation by itself.. The item to secure becomes analyse margin, product mix and profitability., with dated evidence that a third party can understand.

The second layer is consistency between documents: Financial statements, P&L, ledgers and tax returns for three years., Revenue by product family, margin, rebates, purchases and management statistics., Inventory list, valuation method, rotation, expired products and slow-moving products., Lease, supplier contracts, employment contracts, remuneration and team organisation.. If those documents tell the same story about which ebitda should be used?, the company saves time during a tax audit, due diligence, refinancing process or accounting migration. If they contradict one another on document each adjustment., the issue should be fixed before any external review.

Finally, management should identify weak signals before they become expensive: Valuing the pharmacy on revenue without reviewing margin.; Buying overvalued, slow-moving or poorly counted inventory.; Forgetting normal remuneration for the future pharmacist-owner.. For valuing a french pharmacy: inventory, margin and adjusted ebitda before acquisition, this review prevents the company from discovering the issue when an investor, lender, tax authority or buyer is already asking precise questions.

1. Rebuild revenue by family: reimbursed medicines, para-pharmacy, equipment, services and exceptional sales.
2. Analyse margin by segment and identify product mix, rebates, purchasing groups and pricing policy.
3. Adjust EBITDA for owner remuneration, non-recurring expenses, rent, personal costs, professional fees, works and exceptional items.
4. Audit inventory: value, rotation, slow-moving products, expiry, seasonality, supplier disputes and inventory method.
5. Stress-test debt: equity, loan, rate, duration, covenants, buyer remuneration and safety margin.
6. Map the patient base and local prescribers (doctors, care homes, health centres): dependence on one prescriber or a large contract is a value risk.
7. Assess the potential of new services (vaccination, testing, pharmaceutical interviews, medication reviews) and digitalisation (robot, click-and-collect) in the post-acquisition trajectory.
8. Prepare negotiation points: price, warranty, inventory clause, seller support and conditions precedent.

• Financial statements, P&L, ledgers and tax returns for three years.
• Revenue by product family, margin, rebates, purchases and management statistics.
• Inventory list, valuation method, rotation, expired products and slow-moving products.
• Lease, supplier contracts, employment contracts, remuneration and team organisation.
• Required investment schedule: works, robot, software, fit-out and equipment.
• Acquisition forecast, financing plan, debt, working capital and pharmacist remuneration.
• Draft purchase agreement, warranties, escrow, inventory clauses and conditions precedent.
• Regulatory elements and authorisations connected to pharmacy operations.

• Valuing the pharmacy on revenue without reviewing margin.
• Buying overvalued, slow-moving or poorly counted inventory.
• Forgetting normal remuneration for the future pharmacist-owner.
• Failing to adjust personal or exceptional seller expenses.
• Underestimating post-acquisition investments and working capital.

Two pharmacies have the same revenue. The first has stable margin, an autonomous team, well-rotating inventory and limited investment needs. The second depends heavily on the owner, carries high inventory, requires works and has margin pressure. Their revenue is identical; their economic value and debt capacity are not. Concretely, on €2M of revenue, the first may show €180,000 of adjusted EBITDA while the second falls to €120,000 once normal owner remuneration and non-recurring charges are neutralised — a third less repayment capacity for the same asking price. The market is often expressed as a percentage of incl.-VAT revenue or a multiple of adjusted EBITDA, but these benchmarks are indicative and highly sensitive to location, product mix (reimbursed medicine versus para-pharmacy) and margin: they never replace the repayment-capacity test that sets the truly financeable price.

A pharmacy-specialised accountant reviews accounts, rebuilds adjusted EBITDA, audits inventory, prepares the bank forecast and challenges price. The accountant also translates accounting findings into negotiation clauses: price, inventory, warranties, seller support and conditions precedent.

Hayot Expertise supports pharmacy buyers and sellers by connecting valuation, financing, tax and post-acquisition management.

• French pharmacy accountant
• French pharmacy accounting guide
• buying a French pharmacy
• valuation and acquisition advisory
• financial points before an LOI

Caution note for Valuing a French pharmacy: inventory, margin and adjusted EBITDA before acquisition: updated on 5 May 2026. Market multiples should never replace a tailored analysis of the pharmacy, its operations and its financing.

• Ordre national des pharmaciens - Pharmacie d officine en France
• Entreprendre.Service-Public.fr - Cession du fonds de commerce
• Google Search Central - Helpful, reliable, people-first content